AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02749968
Drug: 0.9% sodium chloride
RxNorm normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
Trial: NCT02496975
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
Trial: NCT03742973
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally.
Trial: NCT03221569
Drug: Intravenous ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.3mg/kg IVPB over 15 minutes
Trial: NCT02171039
Drug: Dabigatran
RxNorm normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02171039
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01231919
Drug: Akt inhibitor MK2206
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01861626
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral administration
Trial: NCT01155336
Drug: The placebo contained 1 gram of corn oil in each capsule.
DrugBank: Corn (DB10572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Pill
Trial: NCT01366326
Drug: Methylnaltrexone bromide
RxNorm normalized name: Methylnaltrexone Bromide
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous MNTX
Trial: NCT02072863
Drug: Oprozomib
RxNorm normalized name: Oprozomib
DrugBank: Oprozomib (DB11991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study subjects will receive oprozomib administered orally.
Trial: NCT02072863
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study subjects will receive melphalan 9 mg/m2.
Trial: NCT02072863
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study subjects will receive prednisone 60 mg/m2.
Trial: NCT02366195
Drug: Talimogene Laherparepvec
RxNorm normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The initial dose of talimogene laherparepvec is up to 4.0 mL of 10\^6 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 10\^8 PFU/mL.
Trial: NCT00348985
Drug: belinostat
RxNorm normalized name: Belinostat
DrugBank: Belinostat (DB05015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00348985
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00202007
Drug: Aripiprazole tablet, 5-30mg/day, oral, 6 weeks
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00202007
Drug: Risperidone tablet, 1-6mg/day, oral, 6 weeks
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01695135
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
Trial: NCT01695135
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 5 mg tablet taken orally twice daily
Trial: NCT01434173
Drug: Moxifloxacin (Avelox, BAY12-8039)
RxNorm normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible patients who are new users of moxifloxacin during the study period. A new user is defined as a person who has a first recorded dispensing of moxifloxacin during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days
Trial: NCT00158717
Drug: Hepsera
RxNorm normalized name: Hepsera
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04410094
Drug: Lazertinib
RxNorm normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazertinib tablets will be administered orally.
Trial: NCT04410094
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole capsules will be administered orally.
Trial: NCT04410094
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin capsules will be administered orally.
Trial: NCT00141206
Drug: varenicline (CP-526,555)
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02256345
Drug: KNO3
RxNorm normalized name: Potassium Nitrate
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Active Comparator
Trial: NCT02256345
Drug: KCl
RxNorm normalized name: KCl
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT02031510
Drug: bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: transversus abdominis plane block bupivacaine 0.25%
Trial: NCT02031510
Drug: bupivacaine-dexmedetomidine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
Trial: NCT01257516
Drug: Pregabalin immediate release, 300 mg
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg immediate release capsule administered twice daily for four days
Trial: NCT01257516
Drug: Pregabalin controlled release, 330 mg
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Two tablets of 330 mg (total dose of 660 mg) given concurrently once daily for four days
Trial: NCT02703298
Drug: TRX-818 capsules
RxNorm normalized name: Trx-818 free acid
DrugBank: Foslinanib (DB16172)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02838758
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Roughly 3cc of lidocaine will be injected near the intermetatarsal neuroma under ultrasound visualization.
Trial: NCT02838758
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Roughly 3cc of saline will be injected near the intermetatarsal neuroma under ultrasound visualization.
Trial: NCT01145846
Drug: Cytarabine plus Daunorubicin [Arm II (AD regimen)]
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)
Trial: NCT00490269
Drug: Dronabinol
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02912741
Drug: Vanish xt Extended Contact Varnish
RxNorm normalized name: pseudoephedrine Extended Release Oral Tablet [Contac Cold]
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: resin modified glass- ionomer cement varnish applied as a thin layer coating and cured
Trial: NCT02912741
Drug: resin infiltration
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low viscous light cure resin applied in layers and cured
Trial: NCT04870060
Drug: Curcumin Lozenges
DrugBank: Cumin (DB10864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin lozenges - 4 lozenges to be chewed BD. Each lozenge contained 100 mg of curcumin and the formulation was Solid Lipid Curcumin Particle (SLCP)
Trial: NCT02695290
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00269516
Drug: pardoprunox
RxNorm normalized name: Pardoprunox
DrugBank: Pardoprunox (DB12061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fixed dose 6 mg
Trial: NCT00269516
Drug: Pardoprunox
RxNorm normalized name: Pardoprunox
DrugBank: Pardoprunox (DB12061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fixed dose 12 mg
Trial: NCT00269516
Drug: Pardoprunox
RxNorm normalized name: Pardoprunox
DrugBank: Pardoprunox (DB12061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-42mg
Trial: NCT01393119
Drug: GTx-758
RxNorm normalized name: GTX-758
DrugBank: GTX-758 (DB14969)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-fluoro-N-( 4-fluorophenyl)-4-hydroxy-N-( 4-hydroxyphenyl) benzamide; a nonsteroidal selective estrogen receptor (ER) a agonist
Trial: NCT02823106
Drug: Verapamil and Citicoline
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dosing strategy will be used.
Trial: NCT03154385
Drug: Rituximab (Mabthera ®) Belimumab (Benlysta ®)
RxNorm normalized name: Belimumab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (Mabthera ®): 1g IV at W0 and W2 Belimumab (Benlysta ®) : 10mg/kg IV, W0 + 2days, W2 + 2 days, W4, W8, W12
Trial: NCT00411996
Drug: indinavir/ritonavir
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IDV/r 600/100 mg BID + rifampicin OD for at least 2 weeks
Trial: NCT00487578
Drug: naratriptan HCl
RxNorm normalized name: naratriptan HCl
DrugBank: Naratriptan (DB00952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naratriptan 2.5mg tablet bid x 30 days OR matching placebo
Trial: NCT00768664
Drug: PF-00299804
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg by continuous oral dosing
Trial: NCT00572078
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID
Trial: NCT00726999
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral gabapentin in load pre-op (15mg/kg) and maintenance 5mg/kg TID for 5 days or discharge
Trial: NCT00726999
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as needed
Trial: NCT03107962
Drug: Pembrolizumab (PD-1 Blocking Antibody)
RxNorm normalized name: Humanized pd-1 blocking antibody hx-008
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: pembrolizumab 2mg/kg, ivgtt (intravenously guttae), d1. Every three weeks for one cycle and two cycles are required at least. Efficacy and safety were evaluated every two cycles.
Trial: NCT01639638
Drug: PROAPOPTOTIC PEPTIDE CIGB 300
RxNorm normalized name: PEPTIDE-T
DrugBank: CIGB 300 (DB16464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
Trial: NCT04020718
Drug: Mailed nicotine replacement therapy
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who report continued smoking at Early or Late assessment (depending on random assignment) will be offered a 4 week supply of patches and/or lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette).
Trial: NCT00561886
Drug: Formoterol
RxNorm normalized name: Formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One inhalation of 24µg Formoterol
Trial: NCT00006000
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00006000
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006000
Drug: semaxanib
RxNorm normalized name: Semaxanib
DrugBank: Semaxanib (DB06436)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04247230
Drug: Tetracaine
RxNorm normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
Trial: NCT00675909
Drug: Aerosolized Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam will be administered via aerosolization (using atomizer) with half of dose in each nostril. Total dose is 0.3mg/kg.
Trial: NCT00675909
Drug: Aerosolized Buccal Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.3mg/kg total dose administered with aerosolization device (atomizer) sprayed onto buccal mucosa inside the cheek on both sides of mouth.
Trial: NCT00675909
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral midazolam 0.5mg/kg
Trial: NCT04146038
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04146038
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04146038
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02788851
Drug: Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication is titrated over a 4-week period with stepwise increments each week. Participants and their significant others will complete ADHD symptom scales at baseline and before each medication visit. Participants also complete a side effects scale at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participant will remain on this dose for the remainder of the study. Additionally, once the optimal dose is reached participants will attend 8 weekly educational sessions about ADHD in adulthood.
Trial: NCT00910754
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate 1000 mg (4 x 250 mg tablets) administered orally once daily.
Trial: NCT00910754
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 5 mg tablets administered orally twice daily.
Trial: NCT04580303
Drug: collagenase clostridium histolyticum
RxNorm normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivered via uniform grid injection techniques.
Trial: NCT01326715
Drug: Mangafodipir (Teslascan)
RxNorm normalized name: mangafodipir
DrugBank: Mangafodipir (DB06796)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gadolinium enhancement on contrast enhanced brain MRI.
Trial: NCT02306577
Drug: STRIBILD
RxNorm normalized name: Stribild
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taking oral 1 STRIBILD tablet once a day for 48 weeks
Trial: NCT03644589
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m2, intravenous (IV) infusion, every 21 days, for 6 cycles Given IV
Trial: NCT02186886
Drug: Golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Physiological Intermolecular Modification Spectroscopy
Trial: NCT01418118
Drug: Dobutamine
RxNorm normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maximum infusion rate of 8mcg/kg/min to increase mean arterial pressure by 30mmHg
Trial: NCT01418118
Drug: Dopexamine
RxNorm normalized name: Dopexamine
DrugBank: Dopexamine (DB12313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum infusion rate of 5mcg/kg/min to increase mean arterial pressure by 30mmHg
Trial: NCT00753012
Drug: Lisdexamfetamine
RxNorm normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine daily until the completion of participation in the clinical trial (up to Week 11 or final study visit). Subjects will start on 30 mg of LDX per day for the first week of treatment. The dose will be increased weekly in 20 mg increments, up to a 70 mg daily (maximum). If significant adverse effects (AE) occur, the daily dose may be reduced by 20 mg. At subsequent visits, a higher dose may be resumed if tolerated. Both cohorts of the study will follow the same treatment plan.
Trial: NCT01492166
Drug: biphasic human insulin 30
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose and timing of dose for each subject was at the discretion of the attending physicians based on current clinical practice guidelines
Trial: NCT03293030
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dupilumab treatment
Trial: NCT01470456
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous
Trial: NCT00924248
Drug: Gadoxetic acid disodium (Primovist, BAY86-4873)
RxNorm normalized name: Gadoxetate Disodium
DrugBank: Gadoxetic acid (DB08884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in daily life clinical practice treatment receiving Primovist according to indication on the label.
Trial: NCT02782286
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients randomised to this arm will receive 0,1 mg/kg intravenous morphine.
Trial: NCT01919086
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m\^2, days 1, 8, 15 and 22
Trial: NCT01919086
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).
Trial: NCT01919086
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression
Trial: NCT02727907
Drug: BCD-033 (interferon beta 1a)
RxNorm normalized name: anacaulase-bcdb
DrugBank: Anacaulase (DB17449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
Trial: NCT02515851
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02727907
Drug: Rebif (interferon beta 1a)
RxNorm normalized name: interferon beta-1a Prefilled Syringe [Rebif]
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks
Trial: NCT01587144
Drug: Lucanthone
RxNorm normalized name: Lucanthone
DrugBank: Lucanthone (DB04967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lucanthone will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.
Trial: NCT01587144
Drug: Temozolomide (TMZ)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ is administered at 75mg/m2 daily for 42 days during the concomitant phase. TMZ is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose can be escalated to 200 mg/m2, if the common terminology criteria (CTC) nonhematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count (ANC) is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs.
Trial: NCT03794180
Drug: TJ003234
RxNorm normalized name: TJ003234
DrugBank: TJ003234 (DB16470)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brownish-yellow liquid containing TJ003234, a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody diluted with normal saline
Trial: NCT00382135
Drug: tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg tadalafil tablet taken by mouth once a day for 40 weeks
Trial: NCT03034915
Drug: Salmeterol 50 mcg via DISKUS
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg). The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.